Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Yang, Mingya [VerfasserIn]   i
 Wang, Lei [VerfasserIn]   i
 Neuber, Brigitte [VerfasserIn]   i
 Wang, Sanmei [VerfasserIn]   i
 Sauer, Tim [VerfasserIn]   i
 Schubert, Maria-Luisa [VerfasserIn]   i
 Hückelhoven-Krauss, Angela [VerfasserIn]   i
 Kleist, Christian [VerfasserIn]   i
 Eckstein, Volker [VerfasserIn]   i
 Sellner, Leopold [VerfasserIn]   i
 Müller-Tidow, Carsten [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
 Schmitt, Michael [VerfasserIn]   i
 Schmitt, Anita [VerfasserIn]   i
Titel:Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy
Verf.angabe:Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Anita Schmitt
E-Jahr:2021
Jahr:26 May 2021
Umfang:13 S.
Fussnoten:Gesehen am 06.07.2021
Titel Quelle:Enthalten in: Frontiers in immunology
Ort Quelle:Lausanne : Frontiers Media, 2010
Jahr Quelle:2021
Band/Heft Quelle:12(2021) vom: 26. Mai, Artikel-ID 670088
ISSN Quelle:1664-3224
Abstract:CAR-T cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant medications that include NSAIDs like COX inhibitors. Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. In addition, several studies have also focused on the anti-neoplastic properties of COX-inhibitors. As the influence of COX-inhibitors on CD19.CAR-T cells is still unknown, we investigated the effect of celecoxib and aspirin on the quantity and quality of CD19.CAR-T cells at different concentrations with special regard to cytotoxicity, activation, cytokine release, proliferation and exhaustion. A significant effect on CAR-T cells could be observed for 0.1 mmol/L of celecoxib and for 4 mmol/L of aspirin. At these concentrations, we found that both COX-inhibitors could induce intrinsic apoptosis of CD19.CAR-T cells showing a significant reduction in the ratio of JC-10red to JC-10green CAR-T cells from 6.46 ± 7.03 to 1.76 ± 0.67 by celecoxib and to 4.41 ± 0.32 by aspirin, respectively. Additionally, the ratios of JC-10red to JC-10green Daudi cells were also decreased from 3.41 ± 0.30 to 0.77 ± 0.06 by celecoxib and to 1.26 ± 0.04 by aspirin, respectively. Although the cytokine release by CD19.CAR-T cells upon activation was not hampered by both COX-inhibitors, activation and proliferation of CAR-T cells were significantly inhibited via diminishing the NF-ĸB signaling pathway by a significant down-regulation (about 45%) of expression of CD27 on CD4+/CD8+ CAR-T cells, followed by a clear decrease of phosphorylated NF-ĸB p65 in both CD4+/CD8+ CAR-T cells by a factor of 1.8. Of note, COX-inhibitors hampered expansion and induced exhaustion of CAR-T cells in an antigen stress assay. Collectively, our findings indicate that the use of COX-inhibitors is a double-edged sword that not only induces apoptosis in tumor cells but also impairs the quantity and quality of CAR-T cells. Therefore, COX-inhibitors should be used with caution in patients with B cell lymphoma under CAR-T cell therapy.
DOI:doi:10.3389/fimmu.2021.670088
URL:kostenfrei: Volltext ; Verlag: https://doi.org/10.3389/fimmu.2021.670088
 kostenfrei: Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2021.670088/full
 DOI: https://doi.org/10.3389/fimmu.2021.670088
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Acetylsalycilic acid
 CD19.CAR-T cells
 Celecoxib
 inhibitors
 NSAIDs
 Persistence
K10plus-PPN:1761975218
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68756406   QR-Code
zum Seitenanfang